Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2025-07-04 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science : Le masitinib reçoit l'autorisation de la FDA et de l'EMA pour l’etude confirmatoire de phase 3 dans le cancer de la prostate métastatique hormono-resistant
Regulatory Filings Classification · 1% confidence The document is a press release from AB Science announcing that the FDA and EMA have authorized a Phase 3 confirmatory study for their drug 'masitinib' in metastatic castration-resistant prostate cancer. It details the study design, the rationale behind the biomarker selection, and provides background on the clinical trial results. This is a standard corporate announcement regarding clinical trial progress and regulatory milestones, which falls under the 'Regulatory Filings' (RNS) category as it is a general corporate announcement of material information that does not fit into more specific categories like earnings releases or annual reports.
2025-07-04 French
AB Science : Résultats de l'Assemblée Générale Mixte du 30 juin 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a press release titled 'RESULTATS DE L'ASSEMBLEE GENERALE MIXTE' (Results of the Combined General Meeting) for AB Science. It provides a detailed breakdown of the voting results for various ordinary and extraordinary resolutions, including quorum information, vote counts, and approval status for each resolution. This content directly matches the definition for 'Declaration of Voting Results & Voting Rights Announcements'.
2025-07-01 French
AB Science provides an update on the renegotiation of loan repayment terms with its financial creditors
Capital/Financing Update Classification · 1% confidence The document is a press release from AB Science announcing a restructuring of its debt obligations, specifically the renegotiation of loan repayment terms with financial creditors. This falls under the category of company financing and capital structure updates. It is not a report publication announcement, nor is it a general regulatory filing, as it specifically details changes to debt repayment schedules and financing agreements.
2025-06-30 English
AB Science fait un point sur la renégociation des modalités de remboursement de ses emprunts avec ses créanciers financiers
Capital/Financing Update Classification · 1% confidence The document is a press release from AB Science detailing the renegotiation of its debt repayment terms with financial creditors, specifically regarding state-guaranteed loans (PGE) and innovation loans. It outlines the specific changes to the capital repayment schedule and the conditions for these changes. This falls under the category of company financing and capital structure updates.
2025-06-30 French
AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease
Regulatory Filings Classification · 1% confidence The document is a press release dated June 23, 2025, from AB Science SA announcing new peer-reviewed data and clinical trial updates regarding their drug masitinib for Alzheimer's disease treatment. It details scientific findings, clinical results (Phase 2B/3 study AB09004), regulatory authorizations (FDA/EU Phase 3 study AB21004), and patent information. This content structure—announcing significant business/scientific updates, often including financial/clinical data summaries, but not being the full regulatory report itself (like a 10-K or IR)—is characteristic of an Earnings Release (ER) or a general press release announcing corporate news. Since it focuses heavily on clinical trial results and scientific progress rather than just quarterly financial highlights, it aligns best with an 'Earnings Release' (ER) which often encompasses key operational and scientific milestones announced concurrently with financial reporting periods, or a general Regulatory Filing (RNS) if ER is too narrow. Given the detailed clinical data presentation and the date structure (suggesting a periodic update), ER is a strong candidate, but since it is a general corporate announcement about scientific progress and clinical trial status, it fits the pattern of an 'Earnings Release' (ER) or a general 'Regulatory Filing' (RNS). Because it is a formal announcement of significant corporate/scientific progress, and not a specific financial report (10-K, IR, MRQ), 'ER' is often used for these types of press releases announcing key operational achievements, especially when tied to a specific date. However, 'RNS' is the fallback for general regulatory announcements. Given the nature of the announcement (scientific breakthrough, clinical trial updates, patent news), it is a significant corporate communication. If this were released alongside quarterly results, it would be an ER. If it's standalone, it's RNS. Since it contains detailed data and is a formal announcement, I will classify it as an Earnings Release (ER) as these often include operational/scientific highlights, or RNS as a safe general category. Given the focus on clinical data and scientific validation, it is most likely an announcement accompanying or preceding a financial report, making ER plausible, but RNS is the most general fit for non-standard regulatory announcements. I will lean towards ER as it is a major corporate update, often released around reporting cycles.
2025-06-23 English
AB Science - De nouvelles données évaluées par des pairs apportent des preuves solides du potentiel du masitinib dans le traitement de la maladie d’Alzheimer
Regulatory Filings Classification · 1% confidence The document is a press release dated June 23, 2025, from AB Science SA, announcing new peer-reviewed data supporting the potential of Masitinib for Alzheimer's disease treatment, referencing ongoing Phase 3 studies, and providing detailed clinical trial results (ADAS-COG scores). This content is characteristic of an official announcement detailing scientific progress and clinical data updates, often released to the market to inform investors about key developments. It is not a full Annual Report (10-K), a formal Audit Report (AR), or a simple Earnings Release (ER) which usually contains only key financial figures. It is a detailed update on drug development and clinical findings. Given the options, this functions as a comprehensive update on the company's core product pipeline and results, which aligns best with an Investor Presentation (IP) or a detailed announcement that might accompany one, but since it is a formal press release detailing scientific and clinical progress, it is most closely related to the type of information shared in an Investor Presentation or a comprehensive update. However, looking strictly at the definitions, it is a detailed announcement of scientific findings and clinical data analysis. Since it is a formal press release announcing significant scientific and clinical progress, and not just a short notice of publication, it is best classified as an Investor Presentation (IP) or a detailed report/update. Given the depth of the data (tables, references to phase trials), it goes beyond a simple Earnings Release (ER) or a general Regulatory Filing (RNS). It strongly resembles the content of an Investor Presentation (IP) which details strategy and financials/pipeline progress. If it were a short announcement saying 'results are attached', it would be RPA/RNS. Since it contains the results and analysis, IP is the most fitting category for detailed pipeline updates.
2025-06-23 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.